Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells

Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has n...

Descripción completa

Detalles Bibliográficos
Autores principales: Bugaut, Hélène, Bruchard, Mélanie, Berger, Hélène, Derangère, Valentin, Odoul, Ludivine, Euvrard, Romain, Ladoire, Sylvain, Chalmin, Fanny, Végran, Frédérique, Rébé, Cédric, Apetoh, Lionel, Ghiringhelli, François, Mignot, Grégoire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3676388/
https://www.ncbi.nlm.nih.gov/pubmed/23762310
http://dx.doi.org/10.1371/journal.pone.0065181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3676388/
https://www.ncbi.nlm.nih.gov/pubmed/23762310
http://dx.doi.org/10.1371/journal.pone.0065181

Ejemplares similares